Product Images Progesterone
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Progesterone NDC 53002-1760 by Rpk Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label Image - lbl530021760
Structural Formula - pro0g 0003 01
Table 1 - pro0g 0003 02
Table 2 - pro0g 0003 03
This seems to be a table showing the mean values of some pharmacokinetic parameters for Estrone and Equilin when combined with Conjugated Estrogens and Progesterone capsules administered to postmenopausal women for 12 days. The table has information on the values of AUCs, Cmax, Tmax, and other parameters for different drugs. The text doesn't provide any other information or context, so it may not be useful for someone who is not familiar with this specific study.*
Table 3 - pro0g 0003 04
Figure 1 - pro0g 0003 05
The text describes a figure that shows the time up to 36 months of treatment, represented on the X-axis. The Y-axis represents the total number of patients left at each time interval, denoted with 'n'. There are four time intervals indicated from 0-3 months, with n=38, to 33-36 months, with n=26. The figure is labeled as "Figure 1" and "Time on Medication". No other information about the nature or purpose of the medication is provided.*
Table 4 - pro0g 0003 06
Table 5 - pro0g 0003 07
Table 6 - pro0g 0003 08
This is a report of adverse reactions in postmenopausal women observed over a period of three years in a placebo-controlled trial with 200mg Progesterone capsules and 0.625mg Conjugated Estrogens. The percentage of patients reporting various reactions is listed, including headache, breast tenderness and pain, depression, additional sweating, urinary problems, abdominal pain, diarrhea, and chest pain. Some patients also reported breast carcinoma, breast excisional biopsy, and cholecystectomy. Vaginal discharge, nausea/vomiting, worry, swelling of hands and feet, vaginal dryness, and constipation were also observed.*
Table 7 - pro0g 0003 09
This text describes adverse reactions reported in a placebo-controlled trial in postmenopausal women who were given 400mg/day of progesterone capsules. The adverse reactions reported included headache, bloating, cramping, diarrhea, muscle and back pain, and coughing. The percentages of patients reporting these adverse events were also provided.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
